Works matching IS 09395555 AND DT 2023 AND VI 102 AND IP 7

Results: 40
    1
    2
    3
    4

    Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG).

    Published in:
    Annals of Hematology, 2023, v. 102, n. 7, p. 1887, doi. 10.1007/s00277-023-05273-8
    By:
    • Rattanathammethee, Thanawat;
    • Norasetthada, Lalita;
    • Bunworasate, Udomsak;
    • Wudhikarn, Kitsada;
    • Julamanee, Jakrawadee;
    • Noiperm, Panarat;
    • Lanamtieng, Theerin;
    • Phiphitaporn, Pisa;
    • Navinpipat, Manassamon;
    • Kanya, Piyapong;
    • Jit-ueakul, Dusit;
    • Wongkhantee, Somchai;
    • Suwannathen, Thanongsak;
    • Chaloemwong, Juthatip;
    • Wong, Peerapon;
    • Makruasi, Nisa;
    • Khuhapinant, Archrob;
    • Prayongratana, Kannadit;
    • Niparuck, Pimjai;
    • Kanitsap, Nonglak
    Publication type:
    Article
    5
    6
    7
    8
    9
    10

    Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response.

    Published in:
    2023
    By:
    • Ferreira, Amanda Pifano Soares;
    • Seguro, Fernanda Salles;
    • Abdo, Andre Ramires Neder;
    • Santos, Fernanda Maria;
    • Maciel, Felipe Vieira Rodrigues;
    • Nardinelli, Luciana;
    • Giorgi, Ricardo Rodrigues;
    • Ruiz, Antonio Roberto Lancha;
    • Ferreira, Milton Pifano Soares;
    • Rego, Eduardo Magalhaes;
    • Rocha, Vanderson;
    • Bendit, Israel
    Publication type:
    Correction Notice
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22

    Estimating prognostic relevant cutoff values for a multiplex PCR detecting BCR::ABL1 in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy in resource-limited settings.

    Published in:
    Annals of Hematology, 2023, v. 102, n. 7, p. 1723, doi. 10.1007/s00277-023-05254-x
    By:
    • Hailu, Saifu;
    • Kinde, Samuel;
    • Cross, Michael;
    • Tsegaye, Aster;
    • Kelemu, Tsehayneh;
    • Seifu, Daniel;
    • Alemayehu, Dawit;
    • Tarekegn, Azeb;
    • Jabessa, Gutema;
    • Abeje, Desalegn;
    • Abebe, Markos;
    • Sherif, Abdulaziz;
    • Tadesse, Fisihatsion;
    • Platzbecker, Uwe;
    • Howe, Rawleigh;
    • Gebremedhin, Amha
    Publication type:
    Article
    23
    24
    25
    26
    27
    28

    Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation.

    Published in:
    Annals of Hematology, 2023, v. 102, n. 7, p. 1915, doi. 10.1007/s00277-023-05228-z
    By:
    • Martino, Massimo;
    • Gori, Mercedes;
    • Porto, Gaetana;
    • Pellicano, Maria;
    • Santoro, Ludovica;
    • Verduci, Chiara;
    • Canale, Filippo Antonio;
    • Loteta, Barbara;
    • Moscato, Tiziana;
    • Alati, Caterina;
    • Ieracitano, Maria Consuelo;
    • Cuzzocrea, Amelia;
    • Altomonte, Maria;
    • Florenzano, Maria Teresa;
    • Morabito, Antonella;
    • Irrera, Giuseppe;
    • Naso, Virginia;
    • Pugliese, Marta;
    • Console, Giuseppe;
    • Ferreri, Anna
    Publication type:
    Article
    29
    30
    31
    32

    Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B-cell lymphoma: results of a multicentric prospective cohort study.

    Published in:
    Annals of Hematology, 2023, v. 102, n. 7, p. 1811, doi. 10.1007/s00277-023-05200-x
    By:
    • Juliette, Pénichoux;
    • Hélène, Lanic;
    • Caroline, Thill;
    • Anne-Lise, Ménard;
    • Vincent, Camus;
    • Aspasia, Stamatoullas;
    • Emilie, Lemasle;
    • Stéphane, Leprêtre;
    • Pascal, Lenain;
    • Nathalie, Contentin;
    • Jerôme, Kraut-Tauzia;
    • Christophe, Fruchart;
    • Leila, Kammoun;
    • Gandhi, Damaj;
    • Agathe, Farge;
    • Caroline, Delette;
    • Romain, Modzelewski;
    • Sandrine, Vaudaux;
    • Louis-Ferdinand, Pépin;
    • Hervé, Tilly
    Publication type:
    Article
    33
    34

    RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma

    Published in:
    Annals of Hematology, 2023, v. 102, n. 7, p. 1773, doi. 10.1007/s00277-023-05196-4
    By:
    • Nowakowski, Grzegorz S.;
    • Yoon, Dok Hyun;
    • Mondello, Patrizia;
    • Joffe, Erel;
    • Peters, Anthea;
    • Fleury, Isabelle;
    • Greil, Richard;
    • Ku, Matthew;
    • Marks, Reinhard;
    • Kim, Kibum;
    • Zinzani, Pier Luigi;
    • Trotman, Judith;
    • Sabatelli, Lorenzo;
    • Waltl, Eva E.;
    • Winderlich, Mark;
    • Sporchia, Andrea;
    • Kurukulasuriya, Nuwan C.;
    • Cordoba, Raul;
    • Hess, Georg;
    • Salles, Gilles
    Publication type:
    Article
    35

    Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response.

    Published in:
    Annals of Hematology, 2023, v. 102, n. 7, p. 1761, doi. 10.1007/s00277-023-05189-3
    By:
    • Ferreira, Amanda Pifano Soares;
    • Seguro, Fernanda Salles;
    • Abdo, Andre Ramires Neder;
    • Santos, Fernanda Maria;
    • Maciel, Felipe Vieira Rodrigues;
    • Nardinelli, Luciana;
    • Giorgi, Ricardo Rodrigues;
    • Ruiz, Antonio Roberto Lancha;
    • Ferreira, Milton Pifano Soares;
    • Rego, Eduardo Magalhaes;
    • Rocha, Vanderson;
    • Bendit, Israel
    Publication type:
    Article
    36
    37
    38
    39
    40